If you visit our website, you know that the use of marijuana in women of reproductive age is on the rise and that we are concerned about it. The FDA has put out a [...]
According to a report published by the CDC in Morbidity and Mortality Weekly Report (MMWR), the use of stimulant medications for the treatment of attention-deficit/hyperactivity disorder (ADHD)Â by reproductive-age women is on the rise. In [...]
We continue to see more and more women of reproductive age using marijuana in various forms. Â According to research published in the Journal of the American Medical Association, there has been a significant increase in [...]
Ms. C is a woman with a long history of bipolar disorder, dating back to her teen years. Â Because she experienced recurrent hypomania and mania every time she attempted to discontinue her treatment, she and [...]
Women with bipolar disorder are at a higher risk for relapse during pregnancy and that the risk is even higher during the postpartum period. Â In addition, women with bipolar disorder are more vulnerable to postpartum [...]
The U.S. Food and Drug Administration (FDA) has proposed major revisions to prescription drug labeling in order to provide more accurate and helpful information on the effects of medications used during pregnancy and breastfeeding. The [...]
While we have adequate data to support the use of SSRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. A new case series documents the outcomes of infants exposed to mirtazapine (Remeron).
Because breastfeeding has many psychological and medical benefits for both the mother and her child, many women would like to breastfeed. However, all medications taken by the mother are secreted into the breast milk. While various studies have addressed the short-term safety of antiepileptic drugs (AEDs) in nursing infants, none have systematically assessed the long-term effects of exposure to these drugs on cognitive development.
Data was presented at the 18th Perinatal Society of Australia and New Zealand (PSANZ) Annual Conference in Perth regarding the use of antidepressants among breastfeeding women. Analyzing the data from the Danish National Birth Cohort [...]
Clinically significant anxiety symptoms are common during the postpartum period and frequently complicate the treatment of postpartum depression. Â Â While SSRIs are indicted for the treatment anxiety symptoms, especially when they co-occur with depression, many women may need to use a benzodiazepine for managing more severe symptoms of anxiety or insomnia.Â
